Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey M Williams

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
ACS Pharmacology & Translational Science|April 17, 2020
Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin ReceptorsMichael L Garelja, Maggie Au, Margaret A Brimble, et al.
Cancer Immunology, Immunotherapy : CII|November 3, 2017
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patientsOlivier Gasser, Katrina J Sharples, Catherine Barrow, et al.
Journal of Medicinal Chemistry|July 1, 2008
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1Lisa S Bertram, Daniel Black, Paul H Briner, et al.
ACS Chemical Biology|October 19, 2017
Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide VaccineRegan J Anderson, Jasmine Li, Lukasz Kedzierski, et al.
Organic & Biomolecular Chemistry|January 19, 2019
Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonistBenjamin J Compton, Kathryn J Farrand, Ching-Wen Tang, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2023
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanomaNathaniel Dasyam, Katrina J Sharples, Catherine Barrow, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
ACS Pharmacology & Translational Science|April 17, 2020
Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin ReceptorsMichael L Garelja, Maggie Au, Margaret A Brimble, et al.
Cancer Immunology, Immunotherapy : CII|November 3, 2017
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patientsOlivier Gasser, Katrina J Sharples, Catherine Barrow, et al.
Journal of Medicinal Chemistry|July 1, 2008
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1Lisa S Bertram, Daniel Black, Paul H Briner, et al.
ACS Chemical Biology|October 19, 2017
Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide VaccineRegan J Anderson, Jasmine Li, Lukasz Kedzierski, et al.
Organic & Biomolecular Chemistry|January 19, 2019
Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonistBenjamin J Compton, Kathryn J Farrand, Ching-Wen Tang, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2023
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanomaNathaniel Dasyam, Katrina J Sharples, Catherine Barrow, et al.
Pageof 3